Newcastle Cancer Centre Pharmacology Group
Major centre working in academia and with pharma / biotech
What we do
We have 20 years experience in conducting clinical pharmacology trials in adult and paediatric oncology settings. We provide essential pharmacokinetic outputs for the interpretation of clinical data.
Our main strengths are in :
Selected Publications
Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, Veal, GJ. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia – a report from the UKALL 2011 trial. Eur J Cancer 2019 (In press)
Hawley, J, Veal, GJ, Errington, J, McDonald, LG, Tweddle, DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma associated spinal cord compression. Ped Blood Cancer 2019 e27825 1-3
Uitrakul, S, Hutton, C, Veal, GJ, Jamieson, D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. Eur J Clin Invest 2019 49: e13115 1-7
Veal, GJ, Amankwatia, EB, Paludetto, M-N, Möcklinghoff, T, Thomson, F, André, N, Ciccolini, J, Chatelut, E. Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances and future opportunities. Ther Drug Monit 2019 41: 142-159
Adamson, PC, Veal, GJ, Womer, RB, Meany, HJ, Bernhardt, MB, Frazier, AL, Balis, FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine based estimates of renal function. Ped Blood Cancer 2019 66: e27672 1-8
Duong, JK, Veal, GJ, Nath, CE, Shaw, PJ, Errington, J, Ladenstein, R, Boddy, AV. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol 2019 85: 136-146
Brock, PR, Maibach, R, Childs, M, Rajput, K, Roebuck, D, Sullivan, MJ, Laithier, V, Ronghe, M, dall'Igna, P, Hiyama, E, Brichard, B, Skeen, J, Mateos, ME, Capra, M, Rangaswami, AA, Veal, GJ, Brugières, L, Perilongo, G, Czauderna, P, Morland, B, Neuwelt, EA. Sodium thiosulfate for protection from cisplatin-induced hearing loss. New Engl J Med 2018 378: 2376-2385
Danilenko, M, Stamp, E, Stocken, DD, Husain, A, Zangarini, M, Cranston, A, Stones, R, Sinclair, N, Hodgson, K, Bowett, SA, Roblin, D, Traversa, S, Plummer, R, Veal, G, Langtry, JAA, Ashworth, A, Burn, J, Rajan, N. Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumours (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018 154: 913-921
Thomas, F, Veal, GJ, El Balkhi S, Lafont, T, Picard, N, Brugières, L, Chatelut, E, Piguet, C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol 2018 82: 361-365
White-Koning, M, Osborne, C, Paci, A, Boddy, AVB, Chatelut, E, Veal, GJ. Investigating the potential impact of dose-banding for systemic anti-cancer therapy (SACT) in the paediatric setting based on pharmacokinetic evidence. Eur J Cancer 2018 91: 56-67
Kim, HY, Veal, GJ, Zhou, F, Boddy, AV. The Role of Solute Carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. Eur J Clin Pharmacol 2018 74: 1575-1584
Veal, GJ, Malik, S, Lupo, M, MacFarlane, S, Lepola, P, Costello, M, Ceci, A, Boué, C, Lecour, L, Otto, A, Rastegari, M, Berry, P. Investigating the roles and training of paediatric research nurses working across Europe - a questionnaire-based survey. BMJ Paediatrics Open 2017 1: e00170 1-7
Zangarini, M, Berry, P, Sludden, J, Raynaud, FI, Banerji, U, Jones, P, Edwards, E, Veal, GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma. Bioanalysis 2017 9: 1001-1010
Vormoor, B, Veal, GJ, Griffin, MJ, Boddy, AV, Irving, J, Minto, L, Case, M, Banerji, U, Swales, KE, Tall, JR, Moore, AS, Toguchi, M, Acton, G, Dyer, K, Schwab, C, Harrison, CJ, Grainger, JD, Lancaster, D, Kearns, P, Hargrave, D, Vormoor, J. A Phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukaemia: challenges to run early phase clinical trials for children with leukaemia. Ped Blood Cancer 2017 64: e26351 1-4
Zangarini, M, Rajan, N, Danilenko, M, Berry, P, Traversa, S, Veal, GJ. Development and validation of LC-MS/MS with in-source CID for the quantification of pegcantratinib in human skin tumours. Bioanalysis 2017 9: 279-288
Gota, V, Chinnaswamy, G, Vora, T, Rath, S, Yadav, A, Gurjar, M, Veal, G, Kurkure, P. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother Pharmacol 2016 78: 763-768
Veal, GJ, Cole, M, Chinnaswamy, G, Sludden, J, Jamieson, D, Errington, J, Malik, G, Hill, CR, Chamberlain, T, Boddy, AV. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer 2016 55: 56-64
Jackson, RK, Irving, JAE, Veal, GJ. Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia. Br J Haem 2016 173: 13-24
Walsh, C, Bonner, JJ, Johnson, TN, Neuhoff, S, Ghazaly, EA, Gribben, JG, Boddy, AV, Veal, GJ. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. Br J Clin Pharmacol 2016 81: 989-998
Errington, J, Malik, G, Evans, J, Baston, J, Parry, A, Price, L, Johnstone, H, Peters, S, Oram, V, Howe, K, Whiteley, E, Tunnacliffe, J, Veal, GJ. Investigating the experiences of childhood cancer patients and parents participating in optional nontherapeutic clinical research studies in the UK – a qualitative study. Ped Blood Cancer 2016 63: 1193-1197
Veal, GJ, Errington, J, Sastry, J, Chisholm, J, Brock, P, Morgenstern, D, Pritchard-Jones, K, Chowdhury, T. Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol 2016 77: 685-692
Siebert, N, Eger, C, Seidel, D, Jüttner, M, Zumpe, M, Wegner, D, Kietz, S, Ehlert, K, Veal, GJ, Siegmund, W, Weiss, M, Loibner, H, Ladenstein, R, Lode, HN. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2. mAbs 2016 8: 604-616
Veal, GJ, Errington, J, Hayden, J, Hobin, D, Murphy, D, Dommett, RM, Tweddle, DA, Jenkinson, H, Picton, S. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer 2015 51: 2022-2030
Research Nurse Training
We provide training to research nurses across the UK to ensure that studies are conducted to the same high standards at all clinical centres, helping to ensure the generation of high quality scientific data.
Our next training day will be held in October 2019
Paediatric Oncology Research Nurse Training Day
Thursday 17th October, 2019
Northern Institute for Cancer Research, Newcastle University
Paediatric Oncology Research Nurse Training Day
Thursday 17th October, 2019
Northern Institute for Cancer Research, Newcastle University
What we use
We have a range of analytical equipment and techniques:
Coming soon...
We will be expanding this website - watch this space!
Clinical Trial Specific guidance
Improved tools for sample shipment
Resources to help Research Nurses
Opportunities to help guide our research
If you would like to discuss development of assays, therapeutic drug monitoring, research nurse training, early phase clinical trials or related activities, then fill in the form below.
Find Us
Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH